NCCN
NCCN Adds Krazati, Lumakras to Updated Pancreatic Cancer Guidelines
The group recommends both drugs, currently approved for lung cancer, for certain KRAS G12C-mutant pancreatic cancer patients based on encouraging data from trials.
An analysis of whole-exome sequencing results presented at AACR suggests many people with hereditary cancer risk variants don't fall under current NCCN guidelines.
NCCN Adds Mirati Therapeutics' Krazati to Guidelines for KRAS-Mutant NSCLC With Brain Metastases
The guidelines suggest Krazati as a systemic therapy option for patients with KRAS G12C-mutant non-small cell lung cancer with central nervous system metastases.
Germline Tests Lack Utility for Black South African Prostate Cancer Patients, JNCCN Study Finds
Due to homogenous data informing germline genetic test development, marketed panels don't provide useful prostate cancer risk assessment to patients of sub-Saharan African ancestry, a study showed.
NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling
The guidelines recognize the importance of molecular profiling in diagnosing, treating, and identifying clinical trial opportunities for children with high-grade gliomas.